3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
26
Lymphoma, Non-Hodgkin
23
Lymphoma
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Myelodysplastic Syndromes
18
Hematologic Neoplasms
18
Melanoma
16
Neoplasm Metastasis
15
Lymphoma, B-Cell
14
Multiple Myeloma
12
Pancreatic Neoplasms
11
Hodgkin Disease
11
Stomach Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Breast Neoplasms
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Uterine Cervical Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Neoplasms, Plasma Cell
5
Kidney Neoplasms
5
Burkitt Lymphoma
5
Myeloproliferative Disorders
4
Interventions
Carboplatin
16
Paclitaxel
9
Cyclophosphamide
8
liposomal doxorubicin
6
Peripheral Blood Stem Cell Transplantation
6
Topotecan
5
Filgrastim
5
pembrolizumab
4
Docetaxel
4
oregovomab
3
veliparib
2
sacituzumab govitecan
2
epacadostat
2
avelumab
2
Thiotepa
2
Taxes
2
STA 9090
2
Nivolumab
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Cisplatin
2
Amifostine
2
talazoparib
1
ribociclib
1
relacorilant
1
ralimetinib
1
poly ICLC
1
phenoxodiol
1
peginterferon alfa-2b
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Ovarian Epithelial
×
fludarabine
×
Clear all
NCT07589543
2026-05-15
EB-DUALNK-OV
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled